Value of [18F]fluorodeoxyglucose positron emission tomography in the management of follicular lymphoma: The end of a dilemma?

Clinical Lymphoma and Myeloma

Volumn 8, Issue 5, 2008, Pages 287-293

  Janikova, Andrea ^a   Bolcak, Karol ^b   Pavlik, Tomas ^c   Mayer, Jiri ^a   Kral, Zdenek ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^c MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Computed tomography; Disease staging; Indolent lymphoma; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; IODINATED CONTRAST MEDIUM; RITUXIMAB; DIAGNOSTIC AGENT;

ABDOMINAL RADIOGRAPHY; ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CLINICAL EXAMINATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PARAAORTIC LYMPH NODE; PELVIS RADIOGRAPHY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; THORAX RADIOGRAPHY; TREATMENT OUTCOME; TREATMENT RESPONSE; WATCHFUL WAITING; DISEASE FREE SURVIVAL; FOLLOW UP; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; PATHOPHYSIOLOGY; RECURRENT DISEASE; TUMOR REGRESSION;

ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; NEOPLASM REGRESSION, SPONTANEOUS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 58149330642     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2008.n.040     Document Type: Article

References (24)

1. Horning SJ. Follicular lymphoma: have we made any progress? Ann Oncol 2000; 11(suppl 1):23-7.
2. Gribben JG, Neuberg D, Freedman AS, et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993; 81:3449-57.
3. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004; 104:1258-65.
4. Bangerter M, Moog F, Buchmann I, et al. Whole-body 2-[F-18]-fluoro- 2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. Ann Oncol 1998; 9:1117-22.
5. Hoh CK, Glaspy J, Rosen P, et al. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med 1997; 38:343-8.
6. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25:579-86.
7. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25:571-8.
8. Elstrom R, Guan L, Baker G, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 2003; 101:3875-6.
9. Tsukamoto N, Kojima M, Hasegawa M, et al. The usefulness of (18)Ffluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification. Cancer 2007; 110:652-9.
10. Schöder H, Noy A, Gönen M, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol 2005; 23:4643-51.
11. Jerusalem G, Beguin Y, Najjar F, et al. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of lowgrade non-Hodgkin's lymphoma (NHL). Ann Oncol 2001; 12:825-30.
12. Karam M, Novak L, Cyriac J, et al. Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas. Cancer 2006; 107:175-83.
13. Wöhrer S, Jaeger U, Kletter K, et al. 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading. Ann Oncology 2006; 17:780-4.
14. Wirth A, Foo M, Seymour JF, et al. Impact of [18f ] fluorodeoxyglucose positron emission tomography on staging and management of earlystage follicular non-hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2008; 71:213-9.
15. Mayer J, Janikova A, Kren L, et al. Persistence of lymph node t(14;18) bearing cells in follicular lymphoma patients in clinical complete remission: proof of principle for maintenance therapy? Haematologica 2007; 92(suppl 1):102.
16. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17:1244.
17. Bishu S, Quigley JM, Bishu SR, et al. Predictive value and diagnostic accuracy of F-18-fluoro-deoxy-glucose positron emission tomography treated grade 1 and 2 follicular lymphoma. Leuk Lymphoma 2007; 48:1548-55.
18. Zinzani PL, Musuraca G, Alinari L, et al. Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma. Clin Lymphoma Myeloma 2007; 7:291-5.
19. Svoboda J, Andreadis C, Elstrom R, et al. Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant 2006; 38:211-6.
20. Kahn ST, Flowers C, Lechowicz MJ, et al. Value of PET restaging after chemotherapy for non-Hodgkin's lymphoma: Implications for consolidation radiotherapy. Int J Radiat Oncol Biol Phys 2006; 66:961-5.
21. Spaepen K, Stroobants S, Verhoef G, et al. Positron emission tomography with [18F] FDG for therapy response monitoring in lymphoma patients. Eur J Nucl Med Mol Imaging 2003; 30(suppl 1):S97-S105.
22. Jerusalem G, Beguin Y, Fassotte MF, et al. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica 2000; 85:613-8.
23. Blum RH, Seymour JF, Wirth A, et al. Frequent impact of [18F] fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma. Clin Lymphoma 2003; 4:43-9.
24. Hernandez-Maraver D, Hernadez-Navarro F, Gomez-Leon N, et al. Positron emission tomography/computed tomography diagnostic accuracy in lymphoma. Br J Haematol 2006; 135:293-302.